**Supplementary table 1: Donor causes of death**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Cause of death** | **D\_ANTI+-NAT+ R\_HCV- (N=210)** | **D\_ANTI+-NAT+ R\_HCV+ (N=1148)** | **D\_ANTI+NAT- R\_HCV- (N=191)** | **D\_ANTI+NAT- R\_HCV+ (N=516)** | **D\_ANTI-NAT- R\_HCV+ (N=6321)** | **D\_ANTI-NAT- R\_HCV- (N=16338)** |
| Anoxia\* | 144 (69%) | 778 (68%) | 138 (72%) | 329 (64%) | 2335 (37%) | 6062 (37%) |
| Cerebrovascular / Stroke | 29 (14%) | 161 (14%) | 30 (16%) | 100 (19%) | 1977 (31%) | 4843 (30%) |
| Head Trauma | 34 (16%) | 181 (16%) | 19 (10%) | 79 (15%) | 1861 (29%) | 5004 (31%) |
| Others | 3 (1%) | 28 (2%) | 4 (2%) | 8 (2%) | 148 (2%) | 429 (3%) |

* P <0.0001 among groups (anoxia due to drug overdose)

**Supplementary table 2: Causes of death among recipients**


|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Response** | **D\_ANTI+NAT-** | **D\_ANTI+-NAT+** | **D\_ANTI+NAT-** | **D\_ANTI+-NAT+** | **D\_ANTI-NAT-** | **D\_ANTI-NAT-** |
| **R\_HCV-** | **R\_HCV-** | **R\_HCV+** | **R\_HCV+** | **R\_HCV+** | **R\_HCV-** |
| **(N=191)** | **(N=210)** | **(N=516)** | **(N=1148)** | **(N=6321)** | **(N=16338)** |
| Death (N) | 12 | 13 | 51 | 107 | 650 | 1477 |
| Cardiovascular | 0 (0%) | 4 (31%) | 9 (18%) | 24 (22%) | 119 (18%) | 365 (25%) |
| Respiratory failure | 1 (8%) | 1 (8%) | 4 (8%) | 8 (7%) | 44 (7%) | 113 (8%) |
| Graft failure | 2 (17%) | 1 (8%) | 3 (6%) | 5 (5%) | 56 (9%) | 104 (7%) |
| Hemorrhage | 0 (0%) | 0 (0%) | 2 (4%) | 5 (5%) | 18 (3%) | 69 (5%) |
| Malignancy | 1 (8%) | 1 (8%) | 20 (39%) | 26 (24%) | 135 (21%) | 129 (9%) |
| Immunosuppressive drug related | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (0%) |
| Renal failure | 0 (0%) | 0 (0%) | 0 (0%) | 2 (2%) | 6 (1%) | 13 (1%) |
| Operative | 2 (17%) | 2 (15%) | 2 (4%) | 6 (6%) | 58 (9%) | 173 (12%) |
| Infection | 3 (25%) | 4 (31%) | 3 (6%) | 14 (13%) | 77 (12%) | 235 (16%) |
| Other/Unknown | 3 (25%) | 0 (0%) | 8 (16%) | 17 (16%) | 137 (21%) | 273 (18%) |

**Supplementary table 3: Multivariate analysis: Risk factors for graft and patient survival:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Effect** | **DF** | **Graft Survival** | | **Patient Survival** | |
| **Wald Chi-Square** | **Pr > ChiSq** | **Wald Chi-Square** | **Pr > ChiSq** |
| Group | 5 | 5.471 | 0.361 | 5.640 | 0.343 |
| Age | 1 | 43.056 | <.0001 | 48.802 | <.0001 |
| BMI | 3 | 24.801 | <.0001 | 23.580 | <.0001 |
| Karnofsky Performance Status | 2 | 67.801 | <.0001 | 70.074 | <.0001 |
| Dialysis prior to transplant | 1 | 41.068 | <.0001 | 42.961 | <.0001 |
| Type 2 diabetes | 1 | 3.855 | 0.05 | 4.095 | 0.043 |
| Ascites- moderate to severe | 1 | 3.978 | 0.046 | 4.343 | 0.037 |
| HE stage 3 or 4 | 1 | 25.379 | <.0001 | 25.870 | <.0001 |
| Albumin | 1 | 7.117 | 0.008 | 7.649 | 0.006 |
| Donor Diabetes | 2 | 11.976 | 0.003 | 10.354 | 0.006 |
| Donor Risk Index (DRI) | 1 | 5.814 | 0.016 | 5.633 | 0.018 |

**Supplementary table 4: Causes of graft loss among recipients**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cause of graft failure | D\_ANTI+NAT-/R\_HCV- | D\_ANTI+-NAT+/R\_HCV- | D\_ANTI+NAT-/R\_HCV+ | D\_ANTI+-NAT+/R\_HCV+ | D\_ANTI-NAT-/R\_HCV+ | D\_ANTI-NAT-/R\_HCV- | Total |
| Infection | 0 | 0 | 3 | 6 | 28 | 64 | 101 |
| Primary non-Function | 0 | 0 | 1 | 3 | 25 | 56 | 85 |
| Chronic rejection | 0 | 1 | 1 | 5 | 12 | 36 | 55 |
| Hepatic Artery Thrombosis | 0 | 0 | 0 | 2 | 16 | 27 | 45 |
| Recurrent disease, NON-HEPATITIS | 0 | 0 | 2 | 3 | 18 | 21 | 44 |
| Acute rejection | 1 | 1 | 0 | 1 | 11 | 26 | 40 |
| Diffuse Cholangiopathy | 2 | 0 | 0 | 2 | 3 | 19 | 26 |
| Other Vascular Thrombosis | 0 | 0 | 0 | 0 | 11 | 12 | 23 |
| HEPATITIS recurrent | 0 | 0 | 1 | 2 | 10 | 4 | 17 |
| Primary graft failure | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| HEPATITIS DeNovo | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Vascular thrombosis | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Total | 3 | 2 | 8 | 24 | 137 | 267 | 441 |

****

**Supplementary figure 1A and 1B: One year graft and patient survival among 6 groups without adjusting for other risk factors**